Olaparib | AZD2281;KU0059436;Olaparib. trade name Lynparza.;KU59436 | PARP

Type	HazMat fee for 500 gram (Estimated)
Excepted Quantity	USD 0.00
Limited Quantity	USD 15-60
Inaccessible (Haz class 6.1), Domestic	USD 80+
Inaccessible (Haz class 6.1), International	USD 150+
Accessible (Haz class 3, 4, 5 or 8), Domestic	USD 100+
Accessible (Haz class 3, 4, 5 or 8), International	USD 200+

规格	价格	会员价	库存	数量
{[ item.pr_size ]}	{[ getRatePrice(item.pr_rmb, 1,1) ]} {[ getRatePrice(item.pr_rmb_sale, 1,1) ]} {[ suihuo_tips(item.pr_am, item.pr_size) ]}	{[ getRatePrice(item.pr_rmb, 1,1) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,1) ]} {[ suihuo_tips(item.pr_am, item.pr_size) ]}	{[ getRatePrice(item.pr_rmb, 1,1) ]}{[ suihuo_tips(item.pr_am, item.pr_size) ]}	{[ getRatePrice(item.pr_rmb_sale, 1,1) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate) ]} {[ getRatePrice(item.pr_rmb,1,item.mem_rate) ]}	现货	咨询	- +

细胞系	检测类型	活动说明	数据源
5637	Growth Inhibition Assay	IC50=7.9286 μM	SANGER
697	Growth Inhibition Assay	IC50=2.84173 μM	SANGER
769-P	Growth Inhibition Assay	IC50=24.8466 μM	SANGER
8505C	Growth Inhibition Assay	IC50=26.4977 μM	SANGER

临床研究

NCT号	适应症或疾病	临床期	招募状态	预计完成时间	地点

NCT02571725	Ovarian Cancer ... 展开 >> Fallopian Tube Cancer Peritoneal Neoplasms 收起 <<	Phase 1 Phase 2	Recruiting	February 2022	United States, Florida ... 展开 >> Moffitt Cancer Center Recruiting Tampa, Florida, United States, 33612 Contact: Eleni Rokakis, BSN, RN 813-745-3593 Eleni.Rokakis@moffitt.org United States, New Mexico Southwest Gynecologic Oncology Associates Recruiting Albuquerque, New Mexico, United States, 87106 Contact: Karen Finkelstein, MD 505-843-7813 University of New Mexico Comprehensive Cancer Center Recruiting Albuquerque, New Mexico, United States, 87131 Contact: Valerie Parks, RN 505-925-0390 vparks@salud.unm.edu Principal Investigator: Sarah F Adams, MD United States, Ohio The Ohio State University Recruiting Columbus, Ohio, United States, 43210 Contact: David M O'Malley, MD 614-685-6411 Contact: Molly Myers 614-685-6411 molly.myers@osumc.edu United States, Virginia University of Virginia Cancer Center Recruiting Charlottesville, Virginia, United States, 22903 Contact: Anne Gabel 434-982-6657 am7bd@virginia.edu 收起 <<
NCT03579784	Advanced Gastric Cancer	Phase 2	Recruiting	April 30, 2020	Korea, Republic of ... 展开 >> Seoul National University Hospital Recruiting Seoul, Korea, Republic of, 110-744 Contact: Do-Youn Oh, MD, PhD 82-2-2072-0701 ohdoyoun@snu.ac.kr 收起 <<
NCT01972217	Metastatic Castration-resistan... 展开 >>t Prostate Cancer 收起 <<	Phase 2	Active, not recruiting	December 31, 2018	-
NCT02893917	Castration Levels of Testoster... 展开 >>one Castration-Resistant Prostate Carcinoma Metastatic Prostate Carcinoma Prostate Adenocarcinoma With Focal Neuroendocrine Differentiation Prostate Carcinoma Metastatic in the Bone Prostate Small Cell Carcinoma PSA Progression Stage IV Prostate Adenocarcinoma AJCC v7 收起 <<	Phase 2	Recruiting	-	United States, California ... 展开 >> UC San Diego Moores Cancer Center Recruiting La Jolla, California, United States, 92093 Contact: Site Public Contact 858-822-5354 cancercto@ucsd.edu Principal Investigator: Rana R. McKay University of California Davis Comprehensive Cancer Center Recruiting Sacramento, California, United States, 95817 Contact: Site Public Contact 916-734-3089 Principal Investigator: Mamta Parikh University of California San Diego Recruiting San Diego, California, United States, 92103 Contact: Site Public Contact 858-822-5354 cancercto@ucsd.edu Principal Investigator: Rana R. McKay United States, Connecticut Smilow Cancer Center/Yale-New Haven Hospital Recruiting New Haven, Connecticut, United States, 06510 Contact: Site Public Contact 203-785-5702 canceranswers@yale.edu Principal Investigator: Joseph W. Kim Yale University Recruiting New Haven, Connecticut, United States, 06520 Contact: Site Public Contact 203-785-5702 canceranswers@yale.edu Principal Investigator: Joseph W. Kim United States, Florida Moffitt Cancer Center Recruiting Tampa, Florida, United States, 33612 Contact: Site Public Contact 800-456-7121 canceranswers@moffitt.org Principal Investigator: Jingsong Zhang United States, Massachusetts Massachusetts General Hospital Cancer Center Recruiting Boston, Massachusetts, United States, 02114 Contact: Site Public Contact 877-726-5130 Principal Investigator: Mary-Ellen Taplin Brigham and Women's Hospital Recruiting Boston, Massachusetts, United States, 02115 Contact: Site Public Contact 888-823-5923 ctsucontact@westat.com Principal Investigator: Mary-Ellen Taplin Beth Israel Deaconess Medical Center Recruiting Boston, Massachusetts, United States, 02215 Contact: Site Public Contact 617-667-9925 Principal Investigator: Mary-Ellen Taplin Dana-Farber Cancer Institute Recruiting Boston, Massachusetts, United States, 02215 Contact: Site Public Contact 877-442-3324 Principal Investigator: Mary-Ellen Taplin United States, Michigan Wayne State University/Karmanos Cancer Institute Recruiting Detroit, Michigan, United States, 48201 Contact: Site Public Contact 313-576-9790 ctoadmin@karmanos.org Principal Investigator: Ulka N. Vaishampayan Weisberg Cancer Treatment Center Recruiting Farmington Hills, Michigan, United States, 48334 Contact: Site Public Contact 313-576-9790 ctoadmin@karmanos.org Principal Investigator: Ulka N. Vaishampayan United States, Ohio Ohio State University Comprehensive Cancer Center Recruiting Columbus, Ohio, United States, 43210 Contact: Site Public Contact 800-293-5066 Jamesline@osumc.edu Principal Investigator: J. P. Monk United States, Pennsylvania University of Pittsburgh Cancer Institute (UPCI) Recruiting Pittsburgh, Pennsylvania, United States, 15232 Contact: Site Public Contact 412-647-8073 Principal Investigator: Leonard J. Appleman United States, Tennessee Vanderbilt University/Ingram Cancer Center Recruiting Nashville, Tennessee, United States, 37232 Contact: Site Public Contact 800-811-8480 Principal Investigator: David D. Chism United States, Virginia Virginia Commonwealth University/Massey Cancer Center Recruiting Richmond, Virginia, United States, 23298 Contact: Site Public Contact mwellons@vcu.edu Principal Investigator: Asit K. Paul 收起 <<
NCT03212742	Malignant Gliomas ... 展开 >> Radiotherapy PARP Inhibitor 收起 <<	Phase 1 Phase 2	Recruiting	June 30, 2022	France ... 展开 >> CHU Not yet recruiting Bordeaux, France Contact: Aymeri HUCHET, MD Principal Investigator: Aymeri HUCHET, MD Centre François Baclesse Recruiting Caen, France, 14076 Contact: Dinu STEFAN, MD 33 2 31 45 50 50 d.stefan@baclesse.unicancer.fr Contact: Jean-Michel GRELLARD Principal Investigator: Dinu STEFAN, MD Sub-Investigator: Julien GEFFRELOT, MD Sub-Investigator: Ioana HRAB, MD Centre léon Bérard Not yet recruiting Lyon, France Contact: Marie-Pierre SUNYACH, MD Principal Investigator: Marie-Pierre SUNYACH, MD Hôpitaux universitaires La Pitié Salpétrière - Charles Foix Not yet recruiting Paris, France Contact: Loic FEUVRET, MD Principal Investigator: Loic FEUVRET, MD Sub-Investigator: Florence LAIGLE-DONADEY, MD Sub-Investigator: Khe HOANG-XUAN, MD Sub-Investigator: Ahmed IBDAIH, Pr Institut Curie Not yet recruiting Paris, France Contact: Hamid MAMMAR, MD Principal Investigator: Hamid MAMMAR, MD Sub-Investigator: Laurence BOZEC LE MOAL, MD Sub-Investigator: Coraline DUBOT, MD Sub-Investigator: Patricia TRESCA, MD Sub-Investigator: Patricia MOISSON, MD Institut Claudius Regaud Not yet recruiting Toulouse, France Contact: Elisabeth MOYAL COHEN-JONATHAN, Pr Principal Investigator: Elisabeth MOYAL COHEN-JONATHAN, Pr Sub-Investigator: Ioana CARPUC, MD Sub-Investigator: Jean-Pierre DELORD, MD Sub-Investigator: Cécile GANDY, MD Sub-Investigator: Carlos Alberto GOMEZ-ROCA, MD Sub-Investigator: Anouchka MODESTO, MD Sub-Investigator: Thibaud VALENTIN, MD 收起 <<
NCT01972217	-		Active, not recruiting	-	-
NCT02000622	Breast Cancer Metastatic ... 展开 >> BRCA 1 Gene Mutation BRCA 2 Gene Mutation 收起 <<	Phase 3	Active, not recruiting	December 31, 2019	-
NCT01460888	Carcinoma of the Oesophagus	Phase 1	Unknown	August 2018	United Kingdom ... 展开 >> The Christie NHS Foundation Trust Not yet recruiting Manchester, United Kingdom, M20 4BX Principal Investigator: Hamid Shiekh, Dr Southampton General Hospital Recruiting Southampton, United Kingdom, SO16 6YD Contact: Andrew Jackson, MD +44(0)2380795386 Andrew.Jackson@uhs.nhs.uk Principal Investigator: Andrew Jackson, Dr 收起 <<
NCT03531840	Mesothelioma	Phase 2	Recruiting	December 1, 2020	United States, Maryland ... 展开 >> National Institutes of Health Clinical Center Recruiting Bethesda, Maryland, United States, 20892 Contact: For more information at the NIH Clinical Center contact National Cancer Institute Referral Office 888-624-1937 收起 <<
NCT02899728	Extensive Stage Lung Small Cel... 展开 >>l Carcinoma 收起 <<	Phase 2	Suspended(Other - Pending prot... 展开 >>ocol amendment) 收起 <<	April 7, 2020	United States, California ... 展开 >> Los Angeles County-USC Medical Center Los Angeles, California, United States, 90033 USC / Norris Comprehensive Cancer Center Los Angeles, California, United States, 90033 Keck Medical Center of USC Pasadena Pasadena, California, United States, 91105 United States, Florida Mayo Clinic in Florida Jacksonville, Florida, United States, 32224-9980 Moffitt Cancer Center Tampa, Florida, United States, 33612 United States, Georgia Emory University Hospital Midtown Atlanta, Georgia, United States, 30308 Emory University Hospital/Winship Cancer Institute Atlanta, Georgia, United States, 30322 United States, Kentucky University of Kentucky/Markey Cancer Center Lexington, Kentucky, United States, 40536 United States, Massachusetts Massachusetts General Hospital Cancer Center Boston, Massachusetts, United States, 02114 Brigham and Women's Hospital Boston, Massachusetts, United States, 02115 Beth Israel Deaconess Medical Center Boston, Massachusetts, United States, 02215 Dana-Farber Cancer Institute Boston, Massachusetts, United States, 02215 United States, Minnesota Mayo Clinic Rochester, Minnesota, United States, 55905 United States, Missouri Siteman Cancer Center at West County Hospital Creve Coeur, Missouri, United States, 63141 Washington University School of Medicine Saint Louis, Missouri, United States, 63110 Siteman Cancer Center at Christian Hospital Saint Louis, Missouri, United States, 63136 Siteman Cancer Center at Saint Peters Hospital Saint Peters, Missouri, United States, 63376 United States, New York Laura and Isaac Perlmutter Cancer Center at NYU Langone New York, New York, United States, 10016 United States, Ohio Case Western Reserve University Cleveland, Ohio, United States, 44106 Ohio State University Comprehensive Cancer Center Columbus, Ohio, United States, 43210 United States, Pennsylvania Thomas Jefferson University Hospital Philadelphia, Pennsylvania, United States, 19107 University of Pittsburgh Cancer Institute (UPCI) Pittsburgh, Pennsylvania, United States, 15232 United States, Virginia University of Virginia Cancer Center Charlottesville, Virginia, United States, 22908 Virginia Commonwealth University/Massey Cancer Center Richmond, Virginia, United States, 23298 收起 <<
NCT02000622	-		Active, not recruiting	-	-
NCT02882308	Squamous Cell Carcinoma of the... 展开 >> Head and Neck 收起 <<	Phase 2	Recruiting	May 2019	Greece ... 展开 >> Euromedica General Clinic of Thessaloniki Recruiting Thessaloníki, Thessaloniki, Greece, 54645 Contact: George Fountzilas, Prof.Emeritus 00302310683136 fountzil@auth.gr University Hospital "Attikon", 2nd Department of Internal Medicine, Division of Oncology Recruiting Athens, Greece, 12462 Contact: Diamanto Psyrri, MD,Ass.Prof 0030 2105831256 dp237@email.med.yale.edu 收起 <<
NCT02485990	Primary Peritoneal Carcinoma	Phase 1 Phase 2	Recruiting	September 2021	United States, Maryland ... 展开 >> Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Recruiting Baltimore, Maryland, United States, 21231 Contact: Maureen Berg, RN 443-287-6602 mberg1@jhmi.edu 收起 <<
NCT02769962	Solid Tumors ... 展开 >>Small Cell Lung Carcinoma Carcinoma, Non-Small-Cell Lung Lung Neoplasms Small Cell Lung Cancer Lung Cancer 收起 <<	Phase 1 Phase 2	Recruiting	December 31, 2026	United States, Maryland ... 展开 >> National Institutes of Health Clinical Center Recruiting Bethesda, Maryland, United States, 20892 Contact: For more information at the NIH Clinical Center contact National Cancer Institute Referral Office 888-624-1937 收起 <<
NCT03575078	Lymphoma	Phase 1	Not yet recruiting	August 23, 2023	-
NCT03127215	Cancers With DNA Repair-Defici... 展开 >>ency 收起 <<	Phase 2	Recruiting	March 31, 2021	Germany ... 展开 >> National Center for Tumordiseases (NCT) Recruiting Heidelberg, Germany, 69120 Contact: R. Schlenk, MD +49622156 ext 6228 studienzentrale@nct-heidelberg.de 收起 <<
NCT03561870	Recurrent IDH ... 展开 >> Mutant High Grade Glioma 收起 <<	Phase 2	Not yet recruiting	June 1, 2021	-
NCT03278717	Ovarian Cancer	Phase 3	Not yet recruiting	December 2023	-
NCT02822157	Ovarian Epithelial Cancer	Phase 2	Recruiting	May 2019	Belgium ... 展开 >> UZLeuven Recruiting Leuven, Belgium Contact: Ignace Vergote +32 16 34 74 19 joke.deroover@uzleuven.be 收起 <<
NCT02684318	Advanced Cancer ... 展开 >> Ovarian Cancer Endometrial Cancer Breast Cancer 收起 <<	Phase 1 Phase 2	Recruiting	October 2019	Spain ... 展开 >> Hospital Reina Sofía Recruiting Córdoba, Andalucía, Spain, 14004 Contact: Maria Jesus Rubio, MD Hospital Marqués de Valdecilla Recruiting Santander, Cantabria, Spain, 39008 Contact: Ana de Juan Hospital Universitario Vall d'Hebron Recruiting Barcelona, Spain, 08035 Contact: Ana Oaknin, MD 0034934894158 opadros@vhio.net Principal Investigator: Ana Oaknin, MD Hospital Ramón y Cajal Recruiting Madrid, Spain, 28034 Contact: Eva Guerra, MD Hospital La Paz Recruiting Madrid, Spain, 28046 Contact: Andrés Redondo, MD Fundación Instituto Valenciano de Oncología Recruiting Valencia, Spain, 46009 Contact: Andrés Poveda, MD 0034961104647 apoveda@fivo.org Principal Investigator: Andrés Poveda, MD 收起 <<
NCT02340611	Ovarian Cancer	Phase 2	Completed	-	Canada, Ontario ... 展开 >> Princess Margaret Cancer Centre Toronto, Ontario, Canada, M5G 2M9 收起 <<
NCT01874353	-		Active, not recruiting	-	-
NCT02418624	Breast Cancer ... 展开 >> Ovarian Cancer Advanced Cancer 收起 <<	Phase 1	Unknown	May 2016	Netherlands ... 展开 >> Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital Recruiting Amsterdam, Netherlands, 1066CX Contact: Regina Von Furstenberg 0031205127495 r.v.furstenberg@nki.nl Contact: Gwen Dackus, MD 0031205126965 g.dackus@nki.nl Principal Investigator: J.H.M. Schellens, MD, PhD 收起 <<
NCT02983799	Relapsed Ovarian Cancer, BRCA ... 展开 >>Mutation, Platinum Sensitivity 收起 <<	Phase 2	Recruiting	May 21, 2020	-
NCT03682289	Clear Cell Renal Cell Carcinom... 展开 >>a Locally Advance Pancreatic Ductal Adenocarcinoma Locally Advanced Malignant Solid Neoplasm Metastatic Malignant Solid Neoplasm Metastatic Renal Cell Carcinoma Metastatic Urothelial Carcinoma Pancreatic Ductal Adenocarcinoma Stage III Pancreatic Cancer AJCC v8 Stage III Renal Cell Cancer AJCC v8 Stage IV Pancreatic Cancer AJCC v8 Stage IV Renal Cell Cancer AJCC v8 收起 <<	Phase 2	Not yet recruiting	March 19, 2023	United States, California ... 展开 >> UCSF Medical Center-Mount Zion Not yet recruiting San Francisco, California, United States, 94115 Contact: Rahul R. Aggarwal 877-837-3222 Principal Investigator: Rahul R. Aggarwal, MD 收起 <<
NCT02755844	Recurrent Endometrial Cancer	Phase 1 Phase 2	Not yet recruiting	November 2019	France ... 展开 >> Centre Hospitalier Lyon Sud Not yet recruiting Pierre Benite, France, 69495 Contact: Benoit YOU Contact: Marine DUPUIS Principal Investigator: Benoit YOU, MD 收起 <<
NCT02686008	Squamous Cell Carcinoma of the... 展开 >> Head and Neck 收起 <<	Phase 1	Not yet recruiting	July 2019	-
NCT01874353	Platinum Sensitive ... 展开 >> BRCA Mutated Relapsed Ovarian Cancer Following Complete or Partial Response to Platinum Based Chemotherapy 收起 <<	Phase 3	Active, not recruiting	June 2, 2021	-
NCT02392676	Platinum Sensitive Relapsed Ov... 展开 >>arian Cancer 收起 <<	Phase 3	Withdrawn(Study is unlikely to... 展开 >> be feasible given the evolving ovarian cancer landscape and alternative studies have the potential to meet future clinical demand.) 收起 <<	June 2019	-
NCT03579316	Recurrent Fallopian Tube Carci... 展开 >>noma Recurrent Ovarian Carcinoma Recurrent Primary Peritoneal Carcinoma 收起 <<	Phase 2	Recruiting	March 31, 2019	United States, Massachusetts ... 展开 >> Dana Farber Cancer Institute Recruiting Boston, Massachusetts, United States, 02215 United States, Texas M D Anderson Cancer Center Recruiting Houston, Texas, United States, 77030 Contact: Robert L. Coleman 713-745-3357 Principal Investigator: Robert L. Coleman 收起 <<
NCT03317392	Castration Levels of Testoster... 展开 >>one Castration-Resistant Prostate Carcinoma Metastatic Malignant Neoplasm in the Bone Prostate Adenocarcinoma PSA Progression 收起 <<	Phase 1 Phase 2	Not yet recruiting	April 30, 2020	-
NCT01813474	Cancer Advanc... 展开 >>ed Solid Malignancies 收起 <<	Phase 1	Completed	-	Japan ... 展开 >> Research Site Chuo-ku, Japan, 104-0045 Research Site Fukuoka-shi, Japan, 811-1395 Research Site Sapporo-shi, Japan, 003-0804 收起 <<
NCT01900028	Solid Tumours	Phase 1	Completed	-	Belgium ... 展开 >> Research Site Gent, Belgium, 9000 Research Site Gent, Belgium Research Site Leuven, Belgium, 3000 Research Site Leuven, Belgium Research Site Liege, Belgium, 4000 Research Site Liege, Belgium Denmark Research site Herlev, Denmark, 2730 Research Site København, Denmark, 2100 Netherlands Research Site Amsterdam, Netherlands, 1081 HV Research Site Maastricht, Netherlands, 6229 HX Research Site Nijmegen, Netherlands, 6525 GA United Kingdom Research Site London, United Kingdom Research Site Newcastle, United Kingdom, NE7 7DN Research Site Sutton, United Kingdom, SM2 5PT 收起 <<
NCT03012321	Prostate Cancer Metastatic Cas... 展开 >>tration-Resistant Abnormal DNA Repair Metastatic Prostate Carcinoma Stage IV Prostate Cancer 收起 <<	Phase 2	Recruiting	January 2022	United States, California ... 展开 >> City of Hope National Medical Center Active, not recruiting Duarte, California, United States, 91010 United States, Florida H. Lee Moffitt Cancer Center and Research Institute Recruiting Tampa, Florida, United States, 33612 Contact: Jingsong Zhang, MD 813-745-4673 Principal Investigator: Jingsong Zhang, MD United States, Illinois Northwestern Medicine Recruiting Chicago, Illinois, United States, 60611 Contact: Maha Hussain, MD, FACP, FASCO 312-695-6180 Principal Investigator: Maha Hussain, MD, FACP, FASCO Sub-Investigator: Alicia K. Morgans, MD, MPH Rush University Cancer Center Recruiting Chicago, Illinois, United States, 60612 Contact: Nicklas Pfanzelter, MD 312-942-5904 Principal Investigator: Nicklas Pfanzelter, MD University of Chicago Recruiting Chicago, Illinois, United States, 60637 Contact: Russell Szmulewitz, MD 773-702-7609 Principal Investigator: Russell Szmulewitz, MD Kellogg Cancer Center - NorthShore University Recruiting Evanston, Illinois, United States, 60201 Contact: Daniel Shevrin, MD 847-570-2515 Principal Investigator: Daniel Shevrin, MD United States, Indiana Indiana University/ Melvin and Bren Simon Cancer Center Recruiting Indianapolis, Indiana, United States, 46202 Contact: Roberto Pili, MD 317-948-8310 Principal Investigator: Roberto Pili, MD United States, Maryland Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Recruiting Baltimore, Maryland, United States, 21231 Contact: Emmanuel Antonarakis, MD 410-502-7528 Principal Investigator: Emmanuel Antonarakis, MD United States, Michigan University of Michigan Health System Recruiting Ann Arbor, Michigan, United States, 48109-5946 Contact: Todd Morgan, M.D. 734-647-8903 Sub-Investigator: Todd Morgan, M.D. Sub-Investigator: Zachery Reichert, M.D., Ph.D. Sub-Investigator: Arul Chinnaiyan, M.D., Ph.D. Sub-Investigator: Scott Tomlins, M.D., Ph.D. Karmanos Cancer Center Recruiting Detroit, Michigan, United States, 48201 Contact: Ulka Vaishampayan, MD 313-745-5111 Principal Investigator: Ulka Vaishampayan, MD United States, Minnesota Mayo Clinic Recruiting Rochester, Minnesota, United States, 55905 Contact: Manish Kohli, M.D. 507-538-3270 Principal Investigator: Manish Kohli, M.D. United States, Missouri Washington University School of Medicine Recruiting Saint Louis, Missouri, United States, 63110 Contact: Joel Picus, MD 314-747-9281 Principal Investigator: Joel Picus, MD United States, New Jersey Rutgers Cancer Institute of New Jersey Active, not recruiting New Brunswick, New Jersey, United States, 08903 United States, New York Weill Cornell Medical College Recruiting New York, New York, United States, 10065 Contact: Himisha Beltran, MD 646-962-2072 Principal Investigator: Himisha Beltran, MD United States, North Carolina University of North Carolina at Chapel Hill Recruiting Chapel Hill, North Carolina, United States, 27514 Contact: Young Whang, MD 919-966-4996 Principal Investigator: Young Whang, MD United States, Utah Huntsman Cancer Institute - University of Utah Recruiting Salt Lake City, Utah, United States, 84112 Contact: Neeraj Agarwal, MD 801-585-0100 Principal Investigator: Neeraj Agarwal, MD United States, Virginia University of Virginia Recruiting Charlottesville, Virginia, United States, 22903 Contact: Robert Dreicer, MD 434-924-9333 Principal Investigator: Robert Dreicer, MD 收起 <<
NCT03459846	Urinary Bladder Neoplasms	Phase 2	Recruiting	June 28, 2021	-
NCT03259503	Malignant Neoplasms Stated as ... 展开 >>Primary Lymphoid Haematopoietic Lymphoma 收起 <<	Phase 1 Phase 2	Not yet recruiting	May 2019	United States, Texas ... 展开 >> University of Texas MD Anderson Cancer Center Not yet recruiting Houston, Texas, United States, 77030 Contact ynieto@mdanderson.org 收起 <<
NCT01813474	-		Completed	-	-
NCT02282020	Relapsed Ovarian Cancer, BRCA ... 展开 >>Mutation, Platinum Sensitivity 收起 <<	Phase 3	Active, not recruiting	January 1, 2021	-
NCT03212274	Advanced Malignant Solid Neopl... 展开 >>asm Glioblastoma IDH1 Gene Mutation IDH2 Gene Mutation Recurrent Cholangiocarcinoma Recurrent Glioma Recurrent Malignant Solid Neoplasm WHO Grade II Glioma WHO Grade III Glioma 收起 <<	Phase 2	Suspended(Other - null)	July 31, 2019	United States, California ... 展开 >> University of California Davis Comprehensive Cancer Center Sacramento, California, United States, 95817 United States, Connecticut Smilow Cancer Center/Yale-New Haven Hospital New Haven, Connecticut, United States, 06510 Yale University New Haven, Connecticut, United States, 06520 United States, District of Columbia MedStar Georgetown University Hospital Washington, District of Columbia, United States, 20007 United States, Maryland Johns Hopkins University/Sidney Kimmel Cancer Center Baltimore, Maryland, United States, 21287 United States, Massachusetts Massachusetts General Hospital Cancer Center Boston, Massachusetts, United States, 02114 Brigham and Women's Hospital Boston, Massachusetts, United States, 02115 Beth Israel Deaconess Medical Center Boston, Massachusetts, United States, 02215 Dana-Farber Cancer Institute Boston, Massachusetts, United States, 02215 United States, Ohio Ohio State University Comprehensive Cancer Center Columbus, Ohio, United States, 43210 United States, Pennsylvania University of Pittsburgh Cancer Institute (UPCI) Pittsburgh, Pennsylvania, United States, 15232 United States, Texas M D Anderson Cancer Center Houston, Texas, United States, 77030 收起 <<
NCT01661868	Ovarian Cancer ... 展开 >> Peritoneal Cancer Fallopian Tube Cancer 收起 <<	Phase 2	Withdrawn(Drug not available.)	-	United States, Massachusetts ... 展开 >> Dana-Farber Cancer Institute Boston, Massachusetts, United States, 02215 收起 <<
NCT03233204	Advanced Malignant Solid Neopl... 展开 >>asm Ann Arbor Stage III Childhood Non-Hodgkin Lymphoma Ann Arbor Stage IV Childhood Non-Hodgkin Lymphoma Deleterious ATM Gene Mutation Deleterious BRCA1 Gene Mutation Deleterious BRCA2 Gene Mutation Deleterious RAD51C Gene Mutation Deleterious RAD51D Gene Mutation Histiocytosis Low Grade Glioma Malignant Glioma Recurrent Childhood Central Nervous System Neoplasm Recurrent Childhood Ependymoma Recurrent Childhood Malignant Germ Cell Tumor Recurrent Childhood Non-Hodgkin Lymphoma Recurrent Childhood Rhabdomyosarcoma Recurrent Childhood Soft Tissue Sarcoma Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor Recurrent Glioma Recurrent Hepatoblastoma Recurrent Langerhans Cell Histiocytosis Recurrent Malignant Solid Neoplasm Recurrent Medulloblastoma Recurrent Neuroblastoma Recurrent Osteosarcoma Refractory Central Nervous System Neoplasm Refractory Langerhans Cell Histiocytosis Refractory Malignant Solid Neoplasm Refractory Neuroblastoma Refractory Non-Hodgkin Lymphoma Rhabdoid Tumor Wilms Tumor 收起 <<	Phase 2	Recruiting	September 30, 2024	-
NCT01844986	Newly Diagnosed ... 展开 >> Advanced Ovarian Cancer FIGO Stage III-IV BRCA Mutation Complete Response Partial Response First Line Platinum Chemotherapy 收起 <<	Phase 3	Active, not recruiting	June 6, 2023	-
NCT01858168	Ewing Sarcoma	Phase 1	Recruiting	July 2020	United States, Massachusetts ... 展开 >> Massachusetts General Hospital Recruiting Boston, Massachusetts, United States, 02114 Contact: Barbara Anderson, RN 617-724-4000 banderson@partners.org Contact: Sienna Durbin, BS 617-724-4000 Principal Investigator: Edwin Choy, MD, PhD Boston Children's Hospital Recruiting Boston, Massachusetts, United States, 02115 Contact: Steven Dubois, MD 617-632-5460 Steven_Dubois@dfci.harvard.edu Brigham and Women's Hospital Recruiting Boston, Massachusetts, United States, 02215 Contact: Melissa Hohos, RN 617-582-7162 mhohos@partners.org Contact: Mark Morley, RN 617-632-3989 mmorley@partners.org Principal Investigator: George Demetri, MD Dana-Farber Cancer Institute Recruiting Boston, Massachusetts, United States, 02215 Contact: Melissa Hohos, RN 617-582-7162 mhohos@partners.org Contact: Mark Morley, RN 617-632-3989 mmorley@partners.org Principal Investigator: George Demetri, MD United States, Tennessee St. Jude's Children's Research Hospital Recruiting Memphis, Tennessee, United States, 38105 Contact: Sara Federico, MD 866-278-5833 sara.federico@stjude.org 收起 <<
NCT03428607	SCLC	Phase 2	Not yet recruiting	June 2020	-
NCT03263650	Prostate Cancer Aggressiveness... 展开 >> Prostate Carcinoma 收起 <<	Phase 2	Recruiting	October 2021	United States, Texas ... 展开 >> University of Texas MD Anderson Cancer Center Recruiting Houston, Texas, United States, 77030 Contact: Ana M. Aparicio, MD 713-792-2830 收起 <<
NCT02489006	Ovarian Cancer ... 展开 >> Fallopian Tube Cancer Neoadjuvant Treatment Debulking Surgical Procedures 收起 <<	Phase 2	Recruiting	June 2019	Canada, Alberta ... 展开 >> Tom Baker Cancer Centre Recruiting Calgary, Alberta, Canada, T2N 4N2 Contact: Prafull Ghatage, M.D. 403-521-3721 Principal Investigator: Prafull Ghatage, M.D. Canada, Ontario Juravinski Cancer Centre Not yet recruiting Hamilton, Ontario, Canada, L8V 5C2 Contact: Holger (Hal) Hirte, M.D. (905) 387-9495 Principal Investigator: Holger (Hal) Hirte, M.D. London Regional Cancer Centre Not yet recruiting London, Ontario, Canada, N6A 4L6 Contact: Stephen Welch, M.D. 416-685-8640 Ottawa Regional Cancer Centre Not yet recruiting Ottawa, Ontario, Canada, K1H 8L6 Contact: Johanne Weberpals, M.D. 519-737-8899 ext. 76462 Principal Investigator: Johanne Weberpals, M.D. Princess Margaret Cancer Centre Recruiting Toronto, Ontario, Canada, M5G 2M9 Contact: Amit Oza, M.D 416-946-2818 Principal Investigator: Amit Oza, M.D Canada, Quebec Hôpital Notre-Dame Not yet recruiting Montréal, Quebec, Canada, H2L 4M1 Contact: Diane Provencher, M.D. 514-890-8000 ext 27244 Principal Investigator: Diane Provencher, M.D. 收起 <<
NCT01851265	Solid Tumours	Phase 1	Completed	-	Belgium ... 展开 >> Research Site Edegem, Belgium, 2650 Research Site Leuven, Belgium, 3000 Research Site Wilrijk, Belgium, 2610 Netherlands Research Site Amsterdam, Netherlands, 1081 HV Research Site Maastricht, Netherlands, 6202 AZ United Kingdom Research Site Glasgow, United Kingdom, G12 0YN Research Site Manchester, United Kingdom, M20 4BX 收起 <<
NCT03732820	Metastatic Castration-resistan... 展开 >>t Prostate Cancer 收起 <<	Phase 3	Recruiting	August 17, 2022	-
NCT02184195	Germline BRCA1/2 Mutations and... 展开 >> Metastatic Adenocarcinoma of the Pancreas 收起 <<	Phase 3	Recruiting	July 31, 2019	-
NCT02324998	Prostate Cancer	Phase 1	Recruiting	July 2018	United Kingdom ... 展开 >> Addenbrooke's Hospital, Cambridge University Hospitals Foundation Trust, Recruiting Cambridge, Cambridgeshire, United Kingdom, CB2 0QQ Contact: Ruth Tysoe, BSc. 01223 348089 ruth.tysoe@addenbrookes.nhs.uk Contact: Simon Pacey, MRCP, Ph.D 01223 769 480 scp46@medschl.cam.ac.uk 收起 <<
NCT01921140	Solid Tumours	Phase 1	Active, not recruiting	December 28, 2018	Belgium ... 展开 >> Research Site Brussels, Belgium, 1090 Research Site Leuven, Belgium, 3000 Research Site Liege, Belgium, 4000 Denmark Research Site Herlev, Denmark, 2730 Research Site København Ø, Denmark, 2100 Netherlands Research Site Maastricht, Netherlands, 6202 AZ Research Site Nijmegen, Netherlands, 6525 GA Research Site Utrecht, Netherlands, 3584 CX United Kingdom Research Site London, United Kingdom, SE1 9RT Research Site Newcastle-Upon-Tyne, United Kingdom, NE7 7DN Research Site Surrey, United Kingdom, SM1 2DL 收起 <<
NCT03544125	Anatomic Stage IV Breast Cance... 展开 >>r AJCC v8 Estrogen Receptor Negative HER2/Neu Negative Progesterone Receptor Negative Prognostic Stage IV Breast Cancer AJCC v8 Triple-Negative Breast Carcinoma 收起 <<	Phase 1	Recruiting	December 16, 2020	United States, Oregon ... 展开 >> OHSU Knight Cancer Institute Recruiting Portland, Oregon, United States, 97239 Contact: Zahi Mitri, MD 503-494-9160 mitri@ohsu.edu Principal Investigator: Zahi Mitri, MD 收起 <<
NCT03009682	Small Cell Lung Cancer	Phase 2	Recruiting	June 2019	Korea, Republic of ... 展开 >> Samsung Medical Center Recruiting Seoul, Korea, Republic of, 135-710 Contact: keunchil Park, PhD 收起 <<
NCT02208375	Breast Cancer ... 展开 >> Malignant Female Reproductive System Neoplasm 收起 <<	Phase 1 Phase 2	Active, not recruiting	November 2021	United States, Texas ... 展开 >> University of Texas MD Anderson Cancer Center Houston, Texas, United States, 77030 收起 <<
NCT03375307	Abnormal DNA Repair ... 展开 >> ATM Gene Mutation ATR Gene Mutation BAP1 Gene Mutation BARD1 Gene Mutation BLM Gene Mutation BRCA1 Gene Mutation BRCA2 Gene Mutation BRIP1 Gene Mutation CHEK1 Gene Mutation CHEK2 Gene Mutation FANCC Gene Mutation FANCD2 Gene Mutation FANCE Gene Mutation FANCF Gene Mutation MEN1 Gene Mutation Metastatic Urothelial Carcinoma MLH1 Gene Mutation MSH2 Gene Mutation MSH6 Gene Mutation MUTYH Gene Mutation NPM1 Gene Mutation PALB2 Gene Mutation PMS2 Gene Mutation POLD1 Gene Mutation POLE Gene Mutation PRKDC Gene Mutation RAD50 Gene Mutation RAD51 Gene Mutation SMARCB1 Gene Mutation Stage III Bladder Urothelial Carcinoma AJCC v6 and v7 Stage IV Bladder Urothelial Carcinoma AJCC v7 STK11 Gene Mutation Urothelial Carcinoma 收起 <<	Phase 2	Not yet recruiting	December 31, 2022	-
NCT02446704	Small Cell Lung Cancer	Phase 1 Phase 2	Recruiting	August 2022	United States, Massachusetts ... 展开 >> Massachusetts General Hospital Recruiting Boston, Massachusetts, United States, 02114 Contact: Anna Farago, MD, PhD 617-724-4000 afarago@mgh.harvard.edu Principal Investigator: Anna Farago, MD, PhD Dana Farber Cancer Institute Recruiting Boston, Massachusetts, United States, 02115 Contact: David Barbie, MD 617-632-6049 dbarbie@partners.org Principal Investigator: David Barbie, MD Beth Israel Deaconess Medical Center Active, not recruiting Boston, Massachusetts, United States, 02215 收起 <<
NCT02506816	-		Unknown	June 2017	Spain ... 展开 >> MedSIR investigative site Recruiting Barcelona, Spain, 08036 MedSIR investigative site Recruiting Cordoba, Spain, 14004 MedSIR Recruiting Madrid, Spain, 28034 MedSIR investigative site Recruiting Madrid, Spain, 28040 MedSIR investigative site Recruiting Valencia, Spain, 46009 收起 <<
NCT03462342	High Grade Serous Carcinoma	Phase 2	Recruiting	December 31, 2021	United States, Pennsylvania ... 展开 >> Gynecology Oncology Division Recruiting Philadelphia, Pennsylvania, United States, 19104 Contact: Reena Rai, MS 215-615-6740 reena.rai@uphs.upenn.edu 收起 <<
NCT01583543	Ewing's Sarcoma	Phase 2	Completed	-	United States, Massachusetts ... 展开 >> Massachusetts General Hospital Boston, Massachusetts, United States, 02115 Brigham and Women's Hospital Boston, Massachusetts, United States, 02215 Dana-Farber Cancer Institute Boston, Massachusetts, United States, 02215 收起 <<
NCT03594396	Breast Neoplasms	Phase 1 Phase 2	Recruiting	April 30, 2020	Korea, Republic of ... 展开 >> Seoul National University Hospital Recruiting Seoul, Korea, Republic of Contact: Seock-Ah Im 82-2-2072-0850 moisa@snu.ac.kr 收起 <<
NCT03598257	Inflammatory Breast Carcinoma	Phase 2	Recruiting	July 31, 2023	United States, Illinois ... 展开 >> Carle Cancer Center Recruiting Urbana, Illinois, United States, 61801 Contact: Site Public Contact 800-446-5532 Research@carle.com Principal Investigator: Kalika P. Sarma United States, Iowa Iowa Methodist Medical Center Recruiting Des Moines, Iowa, United States, 50309 Contact: Site Public Contact 515-241-6727 Principal Investigator: Robert J. Behrens United States, Montana Bozeman Deaconess Hospital Recruiting Bozeman, Montana, United States, 59715 Contact: Site Public Contact 406-969-6060 mccinfo@mtcancer.org Principal Investigator: Benjamin T. Marchello United States, Nebraska Nebraska Methodist Hospital Recruiting Omaha, Nebraska, United States, 68114 Contact: Site Public Contact 402-354-5144 Principal Investigator: Kirsten M. Leu United States, Oklahoma University of Oklahoma Health Sciences Center Recruiting Oklahoma City, Oklahoma, United States, 73104 Contact: Site Public Contact 405-271-8777 ou-clinical-trials@ouhsc.edu Principal Investigator: Sobia Nabeel United States, Oregon Providence Saint Vincent Medical Center Recruiting Portland, Oregon, United States, 97225 Contact: Site Public Contact 503-215-2614 CanRsrchStudies@providence.org Principal Investigator: Gary E. Goodman 收起 <<
NCT02889900	Recurrent Platinum Resistant O... 展开 >>varian Cancer 收起 <<	Phase 2	Recruiting	December 20, 2019	-
NCT01583543	-		Completed	-	-
NCT03772561	Solid Tumor, Adult	Phase 1	Recruiting	December 31, 2023	Singapore ... 展开 >> National University Hospital Recruiting Singapore, Singapore, 119074 Contact: David SP Tan 65 6779 5555 david_sp_tan@nuhs.edu.sg 收起 <<
NCT03570476	ATM Biallelic Inactivation ... 展开 >> ATM Gene Mutation ATM Monoallelic Inactivation BRCA1 Biallelic Inactivation BRCA1 Gene Mutation BRCA2 Biallelic Inactivation BRCA2 Gene Mutation FANCA Biallelic Inactivation Homologous Recombination Deficiency PALB2 Biallelic Inactivation PALB2 Gene Mutation Prostate Adenocarcinoma Without Evidence of Neuroendocrine Differentiation Stage I Prostate Cancer AJCC v8 Stage II Prostate Cancer AJCC v8 Stage IIA Prostate Cancer AJCC v8 Stage IIB Prostate Cancer AJCC v8 Stage IIC Prostate Cancer AJCC v8 收起 <<	Phase 2	Recruiting	January 1, 2022	United States, Washington ... 展开 >> Fred Hutch/University of Washington Cancer Consortium Recruiting Seattle, Washington, United States, 98109 Contact: Robert B. Montgomery 206-598-0860 rbmontgo@uw.edu Principal Investigator: Robert B. Montgomery 收起 <<
NCT03057145	Solid Tumor	Phase 1	Recruiting	February 25, 2023	United States, Massachusetts ... 展开 >> Dana Farber Cancer Institute Recruiting Boston, Massachusetts, United States, 02215 Contact: Khanh Do, MD 617-632-6992 Principal Investigator: Khanh Do, MD 收起 <<
NCT02398058	Soft Tissue Sarcoma ... 展开 >> Bone Tumor 收起 <<	Phase 1	Active, not recruiting	January 2019	Italy ... 展开 >> Fondazione del Piemonte per l'Oncologia IRCC Candiolo Candiolo, Torino, Italy, 10060 Istituti Ortopedici Rizzoli - Unit of Chemotherapy of Muscoloskeletal Tumors Bologna, Italy, 40136 Istituto Nazionale Tumori - Unit of Medical Oncology Milano, Italy, 20133 收起 <<
NCT01758731	Squamous Cell Carcinoma of the... 展开 >> Head and Neck 收起 <<	Phase 1	Completed	-	United States, Colorado ... 展开 >> University of Colorado Denver Denver, Colorado, United States, 80045 收起 <<
NCT02681562	Breast Cancer ... 展开 >> Triple Negative Breast Cancer 收起 <<	Phase 2	Unknown	-	-
NCT01929603	Solid Tumours	Phase 1	Completed	-	Belgium ... 展开 >> Research Site Edegem, Belgium Research Site Gent, Belgium Research Site Wilrijk, Belgium Netherlands Research Site Amsterdam, Netherlands Research Site Maastricht, Netherlands 收起 <<
NCT02032823	Breast Cancer	Phase 3	Recruiting	November 27, 2028	-
NCT01623349	Ovarian Cancer ... 展开 >> Breast Cancer 收起 <<	Phase 1	Active, not recruiting	December 2019	United States, Massachusetts ... 展开 >> Massachusetts General Hospital Boston, Massachusetts, United States, 02114 Beth Israel Deaconess Medical Center Boston, Massachusetts, United States, 02215 Dana-Farber Cancer Institute Boston, Massachusetts, United States, 02215 United States, New York Memorial Sloan-Kettering Cancer Center New York, New York, United States, 10065 United States, Texas MD Anderson Cancer Center Houston, Texas, United States, 77230 收起 <<
NCT02229656	Laryngeal Cancer Stage II ... 展开 >> Laryngeal Cancer Stage III Carcinoma, Squamous Cell Head and Neck Neoplasms 收起 <<	Phase 1	Recruiting	August 2020	Netherlands ... 展开 >> The Netherlands Cancer Institute Recruiting Amsterdam, Netherlands, 1066 CX Contact: Marcel Verheij, MD, PhD +31 20 512 2153 m.verheij@nki.nl Contact: Rosemarie de Haan, MD +31 20 512 9085 ro.d.haan@nki.nl Principal Investigator: Marcel Verheij, MD, PhD Sub-Investigator: Margot Tesselaar, MD, PhD Sub-Investigator: Abrahim Al-Mamgani, MD, PhD 收起 <<
NCT02511795	Refractory Solid Tumours ... 展开 >> Relapsed Small Cell Lung Cancer (SCLC) 收起 <<	Phase 1	Recruiting	September 27, 2019	United States, Colorado ... 展开 >> Research Site Recruiting Denver, Colorado, United States, 80218 United States, Florida Research Site Recruiting Sarasota, Florida, United States, 34232 United States, New York Research Site Recruiting New York, New York, United States, 10033 United States, Tennessee Research Site Recruiting Nashville, Tennessee, United States, 37203 United States, Texas Research Site Recruiting Houston, Texas, United States, 77030 Canada, Ontario Research Site Active, not recruiting Toronto, Ontario, Canada, M5G 2M9 收起 <<
NCT02787642	Soft-tissue Sarcoma	Phase 1	Recruiting	December 2020	France ... 展开 >> Institut Bergonié Recruiting Bordeaux, France, 33076 Contact: Paul SARGOS, MD s.sargos@bordeaux.unicancer.fr Centre Oscar Lambret Not yet recruiting Lille, France, 59020 Contact: Nicolas PENEL, MD-PhD n-penel@o-lambret.fr Centre Léon Bérard Recruiting Lyon, France, 69373 Contact: Marie-Pierre SUNYACH, MD marie-pierre.sunyach@lyon.unicancer.fr Institut du Cancer de Montpellier Not yet recruiting Montpellier, France, 34298 Contact: Carmen LLACER-MOSCARDO, MD carmen.llacer@icm.unicancer.fr Institut Claudius Regaud - IUCT Recruiting Toulouse, France, 31052 Contact: Christine CHEVREAU, MD chevreau.christine@iuct-oncopole.fr Institut Gustave Roussy Not yet recruiting Villejuif, France, 94800 Contact: Axel LE CESNE, MD axel.lecesne@gustaveroussy.fr 收起 <<
NCT03161132	Advanced Ovarian Cancer	Phase 2	Recruiting	December 2020	Spain ... 展开 >> Corporación Sanitaria Parc Taulí Recruiting Sabadell, Barcelona, Spain Contact: Yolanda García García, M.D. +34 93 724 00 84 ygarcia@tauli.cat Principal Investigator: Yolanda García García, M.D. Hospital Universitario de Gran Canaria Doctor Negrín Recruiting Palmas de Gran Canaria, Gran Canaria, Spain Contact: Uriel Bohn Sarmiento, M.D. +34 928 450 400 ubosar@gmail.com Principal Investigator: Uriel Bohn Sarmiento, M.D. Hospital Son Llatzer Recruiting Palma De Mallorca, Mallorca, Spain Contact: María Iglesias González, M.D. +34 871 202 000 ext 2103 miglegon@hsll.es Principal Investigator: María Iglesias González, M.D. Hospital Universitario Ramón y Cajal Recruiting Madrid, Spain, 28034 Contact: Alfonso Cortés, M.D. +34 91 336 80 00 acsalgado86@gmail.com Principal Investigator: Alfonso Cortés, M.D. Hospital Universitario 12 de Octubre Recruiting Madrid, Spain Contact: Luis Manso Sánchez, M.D. +34 913908003 luis_manso@hotmail.com Principal Investigator: Luis Manso Sánchez, M.D. Hospital Universitario Virgen del Rocío Recruiting Sevilla, Spain Contact: Elisa Calvo García, M.D. +34 955 013 068 elisa.calvo.garcia@gmail.com Principal Investigator: Elisa Calvo García, M.D. Hospital Universitario y Politécnico La Fe Recruiting Valencia, Spain, 46009 Contact: Ana Santaballana, M.D. +34 961 244 188 santaballa_ana@gva.es Principal Investigator: Ana Santaballa, M.D. Hospital Clínico Universitario de Valencia Recruiting Valencia, Spain Contact: José A Pérez Fidalgo, M.D. +34 963862625 japfidalgo@msn.com Principal Investigator: José A Pérez Fidalgo, M.D. 收起 <<
NCT02227082	Locally Advanced Malignant Neo... 展开 >>plasm Inflammatory Breast Carcinoma Triple-Negative Invasive Breast Carcinoma 收起 <<	Phase 1	Recruiting	August 2020	Netherlands ... 展开 >> The Netherlands Cancer Institute Recruiting Amsterdam, Netherlands, 1066 CX Contact: Gabe Sonke, MD, PhD + 31 20 512 29251 g.sonke@nki.nl Contact: Rosemarie de Haan, MD + 31 20 512 9085 ro.d.haan@nki.nl Principal Investigator: Gabe Sonke, MD, PhD 收起 <<
NCT03330847	Metastatic Triple Negative Bre... 展开 >>ast Cancer 收起 <<	Phase 2	Recruiting	January 20, 2021	-
NCT03641755	Breast Cancer	Phase 1 Phase 2	Recruiting	June 22, 2025	United States, Massachusetts ... 展开 >> Dana Farber Cancer Institute Recruiting Boston, Massachusetts, United States, 02215 Contact: Sara M. Tolaney, MD MPH 617-632-2335 Sara_Tolaney@dfci.harvard.edu Principal Investigator: Sara M. Tolaney, MD MPH Broad Institute of MIT Active, not recruiting Cambridge, Massachusetts, United States, 02142 收起 <<
NCT03106987	Epithelial Ovarian Cancer	Phase 3	Recruiting	May 7, 2021	-
NCT01682772	Adenocarcinoma of the Prostate	Phase 2	Recruiting	December 2019	United Kingdom ... 展开 >> Royal Marsden NHS Foundation Trust Recruiting Sutton, Surrey, United Kingdom, SM2 5PT University College Hospital London Not yet recruiting London, United Kingdom, NW1 2BU 收起 <<
NCT03432897	Prostate Cancer ... 展开 >> Adenocarcinoma of the Prostate 收起 <<	Phase 2	Recruiting	September 2021	United States, Rhode Island ... 展开 >> Lifespan Cancer Institute: The Miriam and Rhode Island Hospitals Recruiting Providence, Rhode Island, United States, 02903 Contact: Kayla Rosati, EdM 401-863-3000 kayla_rosati@brown.edu Principal Investigator: Anothony Mega, MD 收起 <<
NCT03745950	Endometrial Carcinoma	Phase 2	Not yet recruiting	December 2024	France ... 展开 >> ICO Paul Papin Not yet recruiting Angers, France Contact: Sophie ABADIE-LACOURTOISIE Institut Sainte Catherine Not yet recruiting Avignon, France Contact: Julien GRENIER CHRU Jean Minjoz Not yet recruiting Besançon, France Contact: Elsa KALBACHER Institut Bergonié Not yet recruiting Bordeaux, France Contact: Anne FLOQUET Centre François Baclesse Not yet recruiting Caen, France Contact: Pierre-Emmanuel BRACHET Centre Jean Perrin Not yet recruiting Clermont-Ferrand, France Contact: Marie-Ange MOURET-REYNIER Centre Hospitalier Intercommunal de Créteil Not yet recruiting Créteil, France Contact: Isabelle COJEAN-ZELEK Centre Georges François Leclerc Not yet recruiting Dijon, France Contact: Leila BENGRINE Institut Daniel Hollard - GHM de Grenoble Not yet recruiting Grenoble, France Contact: Claire GARNIER TIXIDRE Clinique Victor Hugo Not yet recruiting Le Mans, France Contact: Hugues BOURGEOIS Centre Oscar Lambret Not yet recruiting Lille, France Contact: Annick CHEVALIER Centre Léon Bérard Not yet recruiting Lyon, France Contact: Pierre HEUDEL Hôpital Saint-Joseph Not yet recruiting Marseille, France Contact: Cyril FOA Centre Hospitalier de Mont-De-Marsan Not yet recruiting Mont-de-Marsan, France Contact: Jérôme DAUBA ICM Val d'Aurelle Not yet recruiting Montpellier, France Contact: Michel FABBRO Centre Azuréen de Cancérologie Not yet recruiting Mougins, France Contact: Rémy LARGILLIER Centre d'Oncologie de Gentilly Not yet recruiting Nancy, France Contact: Célia ROEMER-BECUWE Hôpital Privé du Confluent SAS Not yet recruiting Nantes, France Contact: Alain LORTHOLARY Centre Antoine Lacassagne Not yet recruiting Nice, France Contact: Philippe FOLLANA CHU de Nîmes Not yet recruiting Nîmes, France Contact: Miruna TIMAR-DAVID CHR d'Orléans Not yet recruiting Orléans, France Contact: Corina CORNILA Groupe Hospitalier Diaconesses Croix Saint-Simon Not yet recruiting Paris, France Contact: Frédéric SELLE HEGP Not yet recruiting Paris, France Contact: Emilie BOISSIER Hôpital Cochin Not yet recruiting Paris, France Contact: Jérôme ALEXANDRE Institut Curie - Hopital Claudius Régaud Not yet recruiting Paris, France Contact: Manuel RODRIGUES Centre Hospitalier Lyon Sud Not yet recruiting Pierre Benite, France Contact: Benoît YOU Centre CARIO - HPCA Not yet recruiting Plérin, France Contact: Anne-Claire HARDY-BESSARD CHU de Poitiers Not yet recruiting Poitiers, France Contact: Nadia RABAN Polyclinique Francheville Not yet recruiting Périgueux, France Contact: Charles-Briac LEVACHE Centre Henri Becquerel Not yet recruiting Rouen, France Contact: Cécile GUILLEMET ICO Centre René Gauducheau Not yet recruiting Saint-Herblain, France Contact: Jean-Sébastien FRENEL Institut de Cancérologie Lucien Neuwirth Not yet recruiting Saint-Priest-en-Jarez, France Contact: Olivier COLLARD Hôpitaux Universitaires de Strasbourg Not yet recruiting Strasbourg, France Contact: Laure DE COCK Institut Claudius Régaud Not yet recruiting Toulouse, France Contact: Laurence GLADIEFF Institut de Cancérologie de Lorraine Not yet recruiting Vandoeuvre les nancy, France Contact: Yolanda FERNANDEZ Gustave Roussy Not yet recruiting Villejuif, France Contact: Alexandra LEARY 收起 <<
NCT03742245	Breast Cancer Metastatic ... 展开 >> Breast Cancer 收起 <<	Phase 1	Not yet recruiting	September 1, 2022	United States, Texas ... 展开 >> Houston Methodist Cancer Center Houston, Texas, United States, 77030 收起 <<
NCT03167619	Triple Negative Breast Cancer	Phase 2	Recruiting	December 2020	United States, North Carolina ... 展开 >> Duke University Recruiting Durham, North Carolina, United States, 27705 Contact: Sarah Sammons, MD 收起 <<
NCT03162627	Malignant Neoplasm of Breast ... 展开 >> Malignant Neoplasms of Digestive Organs Malignant Neoplasms of Female Genital Organs Malignant Neoplasms of Male Genital Organs Malignant Neoplasms of Thyroid and Other Endocrine Glands 收起 <<	Phase 1	Recruiting	August 2026	United States, Texas ... 展开 >> University of Texas MD Anderson Cancer Center Recruiting Houston, Texas, United States, 77030 Contact swestin@mdanderson.org 收起 <<
NCT03470805	Ovarian Cancer	Phase 2	Recruiting	June 2021	Spain ... 展开 >> ICO Badalona Not yet recruiting Badalona, Spain Contact: Margarita Romeo, MD Principal Investigator: Margarita Romeo, MD H Reina Sofía Cordoba Not yet recruiting Cordoba, Spain, 14004 Contact: Maria Jesus Rubio, MD Principal Investigator: Maria Jesus Rubio, MD Hospital de Guadalajara Not yet recruiting Guadalajara, Spain Contact: Javier Cassinello, MD Principal Investigator: Javier Cassinello, MD Complejo Hospitalario de Jaen Not yet recruiting Jaén, Spain Contact: Fernando Gálvez, MD Principal Investigator: Fernando Gálvez, MD Hospital de Jerez de la Frontera Not yet recruiting Jerez De La Frontera, Spain Contact: Maria del Mar Gordon, MD Principal Investigator: Maria del Mar Gordon, MD Hospital Lucus Augusti Not yet recruiting Lugo, Spain Contact: Lorena Cadavid, MD Principal Investigator: Lorena Cadavid, MD Hospital Universitario La Paz Recruiting Madrid, Spain, 28046 Contact: Andrés Redondo, MD Principal Investigator: Andrés Redondo Fundación Jimenez Diaz Not yet recruiting Madrid, Spain Contact: Victoria Casado, MD Principal Investigator: Victoria Casado, MD Hospital Ramon y Cajal Recruiting Madrid, Spain Contact: Eva Guerra, MD Principal Investigator: Eva Guerra, MD Hospital Universitario 12 de Octubre Not yet recruiting Madrid, Spain Contact: Luis Manso Sánchez, M.D. Principal Investigator: Luis Manso Sánchez, M.D. Hospital Universitario Puerta de Hierro Not yet recruiting Madrid, Spain Contact: Constanza Maximiano, MD Principal Investigator: Constanza Maximiano, MD Hospital Clinico Universitario Virgen Arrixaca Recruiting Murcia, Spain Contact: Jerónimo Martínez, MD Principal Investigator: Jerónimo Martínez, MD Hospital Universitario de Valdecilla Recruiting Santander, Spain, 39008 Contact: Ana de Juan, MD Principal Investigator: Ana de Juan, MD Hospital Universitario Virgen del Rocío Recruiting Sevilla, Spain Contact: Puri Estévez García, M.D. Principal Investigator: Puri Estévez García, M.D. Hospital Virgen Macarena Not yet recruiting Sevilla, Spain Contact: Ana Grueso López, MD Principal Investigator: Ana Grueso López, MD Instituto Valenciano de Oncología Not yet recruiting Valencia, Spain, 46009 Contact: Ignacio Romero, MD Principal Investigator: Ignacio Romero 收起 <<
NCT03742895	Advanced Solid Neoplasms	Phase 2	Recruiting	April 30, 2023	United States, Nebraska ... 展开 >> Southeast Nebraska Cancer Center ( Site 0051) Recruiting Lincoln, Nebraska, United States, 68510 Contact: Study Coordinator 402-327-7363 收起 <<
NCT03205761	Advanced Breast Cancer	Phase 2	Recruiting	January 2020	Spain ... 展开 >> Hospital Universitario Germans Trias i Pujol Recruiting Badalona, Barcelona, Spain, 08916 Hospital Universitario San Joan de Reus Recruiting Reus, Tarragona, Spain, 43204 Hospital del Mar Recruiting Barcelona, Spain, 08003 Hospital Universitario Vall d´Hebron Recruiting Barcelona, Spain, 08035 Hospital Clinic i Provincial Recruiting Barcelona, Spain, 08036 Hospital de la Santa Creu i Sant Pau Recruiting Barcelona, Spain, 08041 Complejo Hospitalario Universitario Reina Sofía Recruiting Cordoba, Spain, 14005 Hospital San Pedro de Alcántara Recruiting Cáceres, Spain, 10003 Hospital General Universitario Gregorio Marañón Recruiting Madrid, Spain, 28007 Centro Oncológico MD Anderson International España Recruiting Madrid, Spain, 28033 MADRID Not yet recruiting Madrid, Spain, 28222 Hospital Universitario Virgen de la Macarena Not yet recruiting Sevilla, Spain, 41009 Instituto Valenciano de Oncología (IVO) Recruiting Valencia, Spain, 46009 Hospital Clínico Universitario de Valencia Recruiting Valencia, Spain, 46010 Hospital Clínico Universitario de Zaragoza "Lozano Blesa" Recruiting Zaragoza, Spain, 50006 Hospital Universitario Miguel Servet Recruiting Zaragoza, Spain, 50009 收起 <<
NCT03286842	HER2-ve Metastatic Breast Canc... 展开 >>er Germline BRCA1/2 Mutations Somatic BRCA1/2 Mutations 收起 <<	Phase 3	Recruiting	November 30, 2020	-
NCT02476968	BRCA or HRR+ Mutated Ovarian C... 展开 >>ancer Patients 收起 <<	Phase 4	Active, not recruiting	October 24, 2019	-
NCT03534492	Bladder Cancer	Phase 2	Not yet recruiting	March 2020	Spain ... 展开 >> Hospital Universitario Central de Asturias Not yet recruiting Oviedo, Asturias, Spain, 33006 Contact: Carlos Álvarez, MD Principal Investigator: Carlos Álvarez, MD ICO Badalona Not yet recruiting Badalona, Barcelona, Spain, 08916 Contact: Albert Font, MD Principal Investigator: Albert Font, MD Clinica IMQ Zorrotzaurre Not yet recruiting Bilbao, Spain Contact: Ricardo Fernández-Rodríguez, MD Principal Investigator: Ricardo Fernández-Rodríguez, MD Hospital San Pedro de Alcántara Not yet recruiting Cáceres, Spain Contact: Ricardo Collado-Martín, MD Principal Investigator: Ricardo Collado-Martín, MD Hospital Universitario Lucus Augusti Not yet recruiting Lugo, Spain, 27003 Contact: Sergio Vázquez, MD Principal Investigator: Sergio Vázquez, MD Hospital Ramón Y Cajal Not yet recruiting Madrid, Spain, 28034 Contact: Pablo Gajate, MD Principal Investigator: Pablo Gajate, MD Hospital Universitario 12 de Octubre Not yet recruiting Madrid, Spain, 28041 Contact: Guillermo de Velasco, MD Principal Investigator: Guillermo de Velasco, MD Hopsital Universitario Madrid Sanchinarro (CIOCC) Not yet recruiting Madrid, Spain Contact: Juan F Rodríguez, MD Principal Investigator: Juan F Rodríguez, MD Hospital Virgen Macarena Not yet recruiting Sevilla, Spain Contact: Juan A Virizuela, MD Principal Investigator: Juan A Virizuela, MD Hospital La Fe Not yet recruiting Valencia, Spain Contact: José Muñoz-Langa, MD Principal Investigator: José Muñoz-Langa, MD 收起 <<
NCT03047135	Prostate	Phase 2	Recruiting	March 1, 2022	United States, Maryland ... 展开 >> Johns Hopkins Hospital Recruiting Baltimore, Maryland, United States, 21231 Contact: Emmanuel Antonarakis, MD 443-287-0553 eantona1@jhmi.edu Contact: Rana Sullivan, RN 410-614-6337 tomalra@jhmi.edu United States, Pennsylvania Thomas Jefferson University Recruiting Philadelphia, Pennsylvania, United States, 19107 Contact: William Kelly, MD 215-503-4490 william.kelly@jefferson.edu Contact: Megan Irving, BS 215-955-9548 megan.irving@jefferson.edu Principal Investigator: William Kelly, MD Allegheny Cancer Center Recruiting Pittsburgh, Pennsylvania, United States, 15212 Contact: Shifeng S Mao, MD 412-359-8373 shifeng.mao@ahn.org Contact: Christy Milburn, MS 412-359-8379 christy.milburn@ahn.org Principal Investigator: Shifeng S Mao, MD 收起 <<
NCT01562210	NSCLC	Phase 1	Recruiting	March 2020	Netherlands ... 展开 >> Netherlands Cancer Institute - Antoni van Leeuwenhoek Ziekenhuis (NKI-AVL) Recruiting Amsterdam, Noord-Holland, Netherlands, 1066 CX Principal Investigator: M. M. van den Heuvel, MD, PhD Principal Investigator: M. Verheij, MD, PhD 收起 <<
NCT03534453	Relapsed Ovarian Cancer ... 展开 >> Following Complete or Partial Response to Platinum Based Chemotherapy Platinum Sensitive 收起 <<	Phase 3	Recruiting	March 1, 2022	China ... 展开 >> Research Site Not yet recruiting Beijing, China, 100021 Research Site Not yet recruiting Beijing, China, 100044 Research Site Recruiting Beijing, China, 100142 Research Site Not yet recruiting Beijing, China, 100730 Research Site Recruiting Changsha, China, 410013 Research Site Recruiting Chengdu, China, 610041 Research Site Recruiting Chongqing, China, 400030 Research Site Not yet recruiting ChongQing, China, 400038 Research Site Not yet recruiting Guangzhou, China, 510060 Research Site Recruiting Hangzhou, China, 310006 Research Site Recruiting Hangzhou, China, 310022 Research Site Recruiting Harbin, China, 150081 Research Site Recruiting Hefei, China Research Site Not yet recruiting Jinan, China, 250012 Research Site Not yet recruiting Nanjing, China, 210009 Research Site Recruiting Shanghai, China, 200011 Research Site Recruiting Shanghai, China, 200032 Research Site Recruiting Shanghai, China, 200080 Research Site Recruiting Shenyang, China, 110016 Research Site Recruiting Tianjin, China, 300060 Research Site Recruiting Tianjin, China Research Site Recruiting Wuhan, China, CN-430030 Research Site Not yet recruiting Xi'an, China Research Site Recruiting Xian, China, 710061 India Research Site Not yet recruiting Ahmedabad, India, 380009 Research Site Not yet recruiting Mumbai, India, 400012 Research Site Not yet recruiting Mumbai, India, 400053 Research Site Not yet recruiting New Delhi, India, 11029 Research Site Not yet recruiting Pune, India, 411001 Research Site Not yet recruiting Vellore, India, 632004 收起 <<
NCT03344965	Metastatic Breast Cancer ... 展开 >> Invasive Breast Cancer Somatic Mutation Breast Cancer (BRCA1) Somatic Mutation Breast Cancer (BRCA2) CHEK2 Gene Mutation ATM Gene Mutation PALB2 Gene Mutation RAD51 Gene Mutation BRIP1 Gene Mutation NBN Gene Mutation 收起 <<	Phase 2	Recruiting	June 30, 2020	United States, Alabama ... 展开 >> University of Alabama at Birmingham Not yet recruiting Birmingham, Alabama, United States, 35294 Principal Investigator: Andres Forero, MD United States, California University of California, San Francisco Not yet recruiting San Francisco, California, United States, 94143 Principal Investigator: Hope Rugo, MD United States, Illinois University of Chicago Not yet recruiting Chicago, Illinois, United States, 60637 Principal Investigator: Rita Nanda, MD United States, Indiana Indiana University Bloomington Not yet recruiting Bloomington, Indiana, United States, 47405 Principal Investigator: Anna Storniolo, MD United States, Maryland Johns Hopkins University Recruiting Baltimore, Maryland, United States, 21218 Contact: Cesar Santa-Maria, MD cesar.santa-maria@northwestern.edu Contact: Ashley Carpenter acarpen7@jhmi.edu Principal Investigator: Cesar Santa-Maria, MD United States, Massachusetts Beth Israel Deaconess Medical Center Recruiting Boston, Massachusetts, United States, 02115 Contact: Nadine Tung, MD ntung@bidmc.harvard.edu Principal Investigator: Nadine Tung, MD Brigham and Women's Hospital Recruiting Boston, Massachusetts, United States, 02115 Dana-Farber Cancer Insitute Recruiting Boston, Massachusetts, United States, 02215 Contact: Judy Garber, MD, MPH 617-632-2282 jegarber@partners.org United States, New York Memorial Sloan Kettering Cancer Center Not yet recruiting New York, New York, United States, 10065 Principal Investigator: Mark Robson, MD United States, North Carolina Duke University Not yet recruiting Durham, North Carolina, United States, 27708 Principal Investigator: Kelly Marcom, MD United States, Pennsylvania University of Pennsylvania Not yet recruiting Philadelphia, Pennsylvania, United States, 19104 Contact: Catherine Rudloff, BSN 215-615-5329 Catherine.rudloff@pennmedicine.upenn.edu Principal Investigator: Payla Shah, MD University of Pittsburgh Recruiting Pittsburgh, Pennsylvania, United States, 15260 Contact: Rometa Pollard 412-641-5430 pollardrr@upmc.edu Principal Investigator: Rachel Jankowitz, MD United States, Washington University of Washignton-Seattle Not yet recruiting Seattle, Washington, United States, 98195 Principal Investigator: Vijayakrishna Gadi, MD 收起 <<
NCT03402841	Non-Germline BRCA Mutated Ovar... 展开 >>ian Cancer 收起 <<	Phase 3	Recruiting	January 4, 2021	-
NCT02533765	Neoplasms, Germ Cell and Embry... 展开 >>onal 收起 <<	Phase 2	Recruiting	December 2018	Italy ... 展开 >> U.O Oncologia Medica, IRST IRCCS Recruiting Meldola, FC, Italy, 47014 Contact: Ugo De Giorgio, MD ugo.degiorgi@irst.emr.it Istituto Nazionale Tumori IRCCS "Fondazione G.Pascale" Recruiting Napoli, Italy, 80131 Contact: Sandro Pignata, MD sandro.pignata@fondazionepascale.it 收起 <<
NCT03434158	Prostate Cancer Metastatic	Phase 2	Recruiting	November 2019	Spain ... 展开 >> Complexo Hospitalario Universitario de Santiago Recruiting Santiago De Compostela, A Coruña, Spain, 15706 Contact: Urbano Anido, MD 0034981950511 urbanoanido@gmail.com Hospital Universitario Central de Asturias Recruiting Oviedo, Asturias, Spain, 33011 Contact: Carlos Álvarez, MD 0034985108000 carlos.alvfer@gmail.com ICO L'Hospitalet Recruiting L'Hospitalet De Llobregat, Barcelona, Spain, 08908 Contact: Lucía Heras, MD 0034932607822 lheras@iconcologia.net Hospital Clínic de Barcelona Recruiting Barcelona, Spain, 08036 Contact: Begoña Mellado, MD 0034932275400 ext 3297 bmellado@clinic.ub.es Complejo Hospitalario Regional Reina Sofía Recruiting Córdoba, Spain, 14004 Contact: María J Méndez, MD 0034957011464 mjosemv@yahoo.es Hospital Universitario 12 de Octubre Recruiting Madrid, Spain, 28041 Contact: José M Sepulveda, MD 0034913908546 jmsepulveda76@gmail.com Fundación Instituto Valenciano de Oncología Recruiting Valencia, Spain, 46009 Contact: María J Juan Fita, MD 0034961104606 mjuanfi81@hotmail.com Hospital Universitario i Politècnic La Fe Recruiting Valencia, Spain, 46026 Contact: David Lorente, MD 0034961244000 davlorente@hotmail.com 收起 <<
NCT02677038	Pancreatic Cancer	Phase 2	Recruiting	November 2020	United States, Texas ... 展开 >> University of Texas MD Anderson Cancer Center Recruiting Houston, Texas, United States, 77030 收起 <<
NCT02855697	Ovarian Cancer	Early Phase 1	Recruiting	December 2020	United Kingdom ... 展开 >> The Christie NHS Foundation Trust Recruiting Manchester, United Kingdom, M20 4BX Contact: Andrew Clamp, MD, PhD 0161 446 3606 Andrew.Clamp@christie.nhs.uk Contact: Catherine Rogers, Nurse 0161 918 7689 catherine.rogers@christie.nhs.uk Principal Investigator: Andrew Clamp 收起 <<
NCT03448718	Metastatic Urothelial Cancer	Phase 2	Recruiting	March 2023	United States, Illinois ... 展开 >> University of Chicago Medical Center Recruiting Chicago, Illinois, United States, 60637 Contact: Glenna Smith Conley 773-834-2143 gsmith6@bsd.uchicago.edu Principal Investigator: Peter O'Donnell, MD United States, New York Icahn School of Medicine at Mount Sinai Recruiting New York, New York, United States, 10029-6542 Contact: Matthew Galsky 212-824-5452 matthew.galsky@mssm.edu United States, Utah Huntsman Cancer Institute University of Utah Recruiting Salt Lake City, Utah, United States, 84112-5550 Contact: Sumati Gupta, MD sumati.gupta@hci.utah.edu Principal Investigator: Sumati Gupta, MD 收起 <<
NCT03109080	Breast Neoplasms, Triple-Negat... 展开 >>ive Breast Neoplasm Malignant Female Radiotherapy Side Effect 收起 <<	Phase 1	Recruiting	July 2021	France ... 展开 >> Institut Curie Recruiting Paris, France, 75005 Contact: Youlia KIROVA, MD 收起 <<
NCT03367689	Breast Cancer	Phase 2	Recruiting	November 30, 2021	Spain ... 展开 >> Hospital del Mar Not yet recruiting Barcelona, Spain Principal Investigator: Sonia Servitja Hospital Universitario A Coruña Not yet recruiting Coruña, Spain Principal Investigator: Lourdes Calvo Onkologikoa Recruiting Donostia, Spain Principal Investigator: Ander Urruticoetxea Hospital Ramón y Cajal Recruiting Madrid, Spain Principal Investigator: Alfonso Cortés Hospital Virgen de la Victoria Not yet recruiting Málaga, Spain Principal Investigator: Antonia Márquez Hospital Sant Joan Not yet recruiting Reus, Spain Principal Investigator: Kepa Amillano Hospital Virgen del Rocio Not yet recruiting Sevilla, Spain Principal Investigator: Manuel Ruiz Instituto Valenciano de oncología Not yet recruiting Valencia, Spain Principal Investigator: María José Juan 收起 <<
NCT02645149	Melanoma	Phase 4	Not yet recruiting	August 2021	Australia, New South Wales ... 展开 >> Royal Prince Alfred Hospital Not yet recruiting Camperdown, New South Wales, Australia, 2050 Contact: Maria Gonzalez 612 9911 7200 maria.gonzalez@melanoma.org.au Principal Investigator: John Thompson Westmead Hospital Westmead, New South Wales, Australia, 2145 Melanoma Institute Australia Not yet recruiting Wollstonecraft, New South Wales, Australia, 2065 Contact: Maria Gonzalez +612 9911 7200 maria.gonzalez@melanoma.org.au Contact: Alex Menzies +612 9911 7200 info@melanoma.org.au Sub-Investigator: Georgina Long Principal Investigator: Alex Menzies 收起 <<
NCT03297606	Lymphoma, Non-Hodgkin ... 展开 >> Multiple Myeloma Advanced Solid Tumors 收起 <<	Phase 2	Recruiting	September 2021	Canada, British Columbia ... 展开 >> BCCA - Vancouver Cancer Centre Recruiting Vancouver, British Columbia, Canada, V5Z 4E6 Contact: Daniel John Renouf 604 877-6000 ext 672357 Canada, Ontario London Regional Cancer Program Recruiting London, Ontario, Canada, N6A 5W9 Contact: Stephen Welch 519 685-8640 Ottawa Hospital Research Institute Recruiting Ottawa, Ontario, Canada, K1H 8L6 Contact: John Hilton 613 737-7700 ext 70179 University Health Network Recruiting Toronto, Ontario, Canada, M5G 2M9 Contact: Lillian Siu 416 946-2911 Canada, Quebec The Jewish General Hospital Recruiting Montreal, Quebec, Canada, H3T 1E2 Contact: Cristiano Ferrario 514 398-8307 收起 <<
NCT02624973	Breast Cancer	Phase 2	Active, not recruiting	June 2030	Norway ... 展开 >> Akershus University Hospital Lørenskog, Akershus, Norway Haukeland University Hospital Bergen, Hordaland, Norway, 5021 Helse Fonna Haugesund, Rogaland, Norway Helse Stavanger Stavanger, Rogaland, Norway Helse Førde Førde, Sogn Og Fjordande, Norway St. Olavs Hospital Trondheim, Sør Trøndelag, Norway Helse Nord/UNN Tromsø, Troms, Norway 收起 <<
NCT03498521	Cancer of Unknown Primary Site	Phase 2	Recruiting	April 16, 2022	-
NCT02338622	Advanced Cancer	Phase 1	Unknown	October 2015	United Kingdom ... 展开 >> Northern Institute for Cancer, Freeman Hospital Recruiting Newcastle, Newcastle upon Tyne, United Kingdom, NE7 7DN Contact: Elizabeth R Plummer, MD +44(0)191 213844 ruth.plummer@newcastle.ac.uk Principal Investigator: Elizabeth R Plummer, MD Royal Marsden NHS Foundation Trust Recruiting Sutton, Surrey, United Kingdom, SM2 5PT Contact: Timothy A Yap, PhD 0208 661 3539 timothy.yap@icr.ac.uk Principal Investigator: Timothy A Yap, PhD 收起 <<
NCT03251612	Colorectal Cancer Metastatic	Phase 2	Recruiting	December 2020	Denmark ... 展开 >> Department of Oncology, Aalborg University Hospital Not yet recruiting Aalborg, Denmark Contact: Mette Yilmaz, MD m.yilmaz@rn.dk Department of Oncology, Rigshospitalet Not yet recruiting Copenhagen, Denmark Contact: Lone N Petersen, MD Lone.Noergaard.Petersen@regionh.dk Departmen of Oncology, Vejle Hospital Recruiting Vejle, Denmark Contact: Lars H Jensen, MD lars.henrik.jensen@rsyd.dk Germany Universitätsklinikum Hamburg - Eppendorf, Universitäres Cancer Center Hamburg (UCCH) Not yet recruiting Hamburg, Germany Contact: Andreas Block, MD block@uke.de 收起 <<
NCT01042379	Breast Neoplasms ... 展开 >> Breast Cancer Breast Tumors 收起 <<	Phase 2	Recruiting	-	-
NCT03155620	Advanced Malignant Solid Neopl... 展开 >>asm Ann Arbor Stage III Childhood Non-Hodgkin Lymphoma Ann Arbor Stage IV Childhood Non-Hodgkin Lymphoma Childhood Langerhans Cell Histiocytosis Histiocytic Sarcoma Juvenile Xanthogranuloma Malignant Glioma Recurrent Central Nervous System Neoplasm Recurrent Childhood Ependymoma Recurrent Childhood Malignant Germ Cell Tumor Recurrent Childhood Medulloblastoma Recurrent Childhood Non-Hodgkin Lymphoma Recurrent Childhood Rhabdomyosarcoma Recurrent Childhood Soft Tissue Sarcoma Recurrent Ewing Sarcoma Recurrent Glioma Recurrent Hepatoblastoma Recurrent Langerhans Cell Histiocytosis Recurrent Malignant Solid Neoplasm Recurrent Neuroblastoma Recurrent Osteosarcoma Recurrent Peripheral Primitive Neuroectodermal Tumor Recurrent Rhabdoid Tumor Refractory Central Nervous System Neoplasm Refractory Childhood Malignant Germ Cell Tumor Refractory Ewing Sarcoma Refractory Glioma Refractory Hepatoblastoma Refractory Langerhans Cell Histiocytosis Refractory Malignant Solid Neoplasm Refractory Medulloblastoma Refractory Neuroblastoma Refractory Non-Hodgkin Lymphoma Refractory Osteosarcoma Refractory Peripheral Primitive Neuroectodermal Tumor Refractory Rhabdoid Tumor Refractory Rhabdomyosarcoma Rhabdoid Tumor Stage III Osteosarcoma AJCC v7 Stage III Soft Tissue Sarcoma AJCC v7 Stage IV Osteosarcoma AJCC v7 Stage IV Soft Tissue Sarcoma AJCC v7 Stage IVA Osteosarcoma AJCC v7 Stage IVB Osteosarcoma AJCC v7 Wilms Tumor 收起 <<	Phase 2	Recruiting	September 30, 2027	-

产品名称	PARP ↓ ↑	PARP1 ↓ ↑	PARP2 ↓ ↑	PARP3 ↓ ↑	纯度
PJ34 HCl	++ PARP, EC50: 20 nM				99%+
Rucaparib phosphate	++++ PARP, Ki: 1.4 nM				99%+
3-Aminobenzamide	++ PARP, IC50: <50 nM				98%
AZD-2461	✔				99%+
BGP-15	✔				99%+
NU1025	+ PARP, IC50: 400 nM				97%
Benzamide	+ PARP, IC50: 3.3 μM				98%
Picolinamide	+ PARP, IC50: 95 μM				98%
AG14361		+++ PARP1, Ki: <5 nM			98+%
Iniparib		✔			98%
Talazoparib		++++ PARP1, IC50: 0.57 nM			99%+
NMS-P118		++ PARP1, Kd: 0.009 μM			98+%
UPF 1069		+ PARP1, IC50: 8.0 μM	++ PARP2, IC50: 0.3 μM		98%
A-966492		++++ PARP1, Ki: 1 nM PARP1, EC50: 1 nM	+++ PARP2, Ki: 1.5 nM		99%+
Veliparib		++ PARP1, Ki: 5.2 nM	+++ PARP2, Ki: 2.9 nM		98%
Niraparib tosylate		+++ PARP1, IC50: 3.8 nM	+++ PARP2, IC50: 2.1 nM		99%+
Stenoparib		++++ PARP1, IC50: 1 nM	++++ PARP2, IC50: 1.2 nM		98%
Olaparib		+++ PARP1, IC50: 5 nM	++++ PARP2, IC50: 1 nM		98%
Niraparib		+++ PARP1, IC50: 3.8 nM	+++ PARP2, IC50: 2.1 nM		98%
ME0328		+ PARP1, IC50: 6.3 μM		+ PARP3, IC50: 0.89 μM	99%+
1. 鼠标悬停在“+”上可以显示相关IC50的具体数值。"+"越多，抑制作用越强。2. "✔"表示该化合物对相应的亚型有抑制作用，但抑制强度暂时没有相关数据。

靶点	PARP1 PARP1, IC50:5 nM PARP2 PARP2, IC50:1 nM
描述	PARP1, also called as Poly(ADP-ribose) polymerase, is involved in the signaling of DNA damage. It can recognize and bind DNA single or double-strand breaks . Thus it possesses various cellular function, including regulation of apoptosis and chromosome stability, gene amplification and transcription, as well as cell division and differentiation. PARP-2 is the closest homolog of PARP1 (~62% similarity in catalytic domain) and compensates for PARP-1 activity in DNA single-strand break repair^[1]. Olaparib, also called as AZD2281 or Ku-0059436, one of the best investigated third-generation PARP inhibitors^[2], can potently inhibit both PARP-1 (IC50=5nM) and PARP-2(IC50=1nM)^[1]. BRCA1-deficient cell lines, such as MDA-MB-436 and HCC1937, were hypersensitive to olaparib than BRCA1- and BRCA2-proficient cell lines (Hs578T, MDA-MB-231 and T47D). Also olaparib shows good pharmacokinetic profiles, oral bioavailability, as well as activity in vivo^[1]. These facilitate olaparib approved for use in recurrent ovarian cancer and germline BRCA HER2-negative metastatic breast cancer^[2].
作用机制	Olaparib occupies the NAD binding pocket at the catalytic site, which has been proposed to trap PARP1 on DNA.^[3]

Dose	Mice: min = 10 mg/kg^[4], max = 200 mg/kg^[5]
Administration	p.o., i.v., i.p.

CAS号	763113-22-0
分子式	C₂₄H₂₃FN₄O₃
分子量	434.46

别名	AZD2281;KU0059436;Olaparib. trade name Lynparza.;KU59436
运输	蓝冰

奥拉帕尼 /Olaparib {[allProObj[0].p_purity_real_show]}

Olaparib 纯度/质量文件产品仅供科研

全球学术期刊中引用的产品

Olaparib 质控信息

Olaparib 生物活性

Olaparib 细胞研究

Olaparib 动物研究

Olaparib 临床研究

Olaparib 参考文献

Olaparib 实验方案

Olaparib 技术信息

最近浏览的产品

大规格询价

摩尔计算器

靶点

总药量计算器

工作液计算器

细胞研究

临床研究

确认信息

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

奥拉帕尼 /Olaparib {[allProObj[0].p_purity_real_show]}

Olaparib 纯度/质量文件 产品仅供科研

全球学术期刊中引用的产品

Olaparib 质控信息

Olaparib 生物活性

Olaparib 细胞研究

Olaparib 动物研究

Olaparib 临床研究

Olaparib 参考文献

Olaparib 实验方案

Olaparib 技术信息

最近浏览的产品

大规格询价

摩尔计算器

靶点

总药量计算器

工作液计算器

细胞研究

临床研究

确认信息

请登录您的专属账户

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

Olaparib 纯度/质量文件产品仅供科研